Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis

Oxidative stress may play a pathogenic role in chronic hepatitis C (CHC). The present study examined the oxidative status in plasma of patients with CHC who received pegylated interferon and ribavirin therapy. The following groups were included: (1) sustained virological response (28 patients), (2) null response (26 patients), (3) breakthrough (24 patients), (4) relapse (24 patients), (5) spontaneous cure (23 patients) and (6) twenty five normal subjects as a control group. Markers of oxidative stress including plasma malondialdehyde, nitric oxide, reduced glutathione, total antioxidant capacity and uric acid as well as serum ALT, AST, alkaline phosphatase, total bilirubin, albumin, prothrombin time were studied. The study indicated significant decline in reduced glutathione and total antioxidant capacity and markedly elevated levels of malondialdehyde and nitric oxide in all groups compared with the controls. Null response group had the highest levels of malondialdehyde and nitric oxide. Nitric oxide was significantly higher in those with null response compared with all other groups and with control subjects. Uric acid was significantly higher in spontaneous cure group compared with all other groups and with the controls. We concluded that CHC patients had increased oxidative stress. The oxidative status in plasma of these patients was not changed by antiviral therapy. The study also showed an important contribution of nitric oxide in null response patients. High serum uric acid did not interfere with the response and/or did not predict the response to antiviral therapy.

[1]  K. Thorlund,et al.  Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Tsukiyama-Kohara Role of Oxidative Stress in Hepatocarcinogenesis Induced by Hepatitis C Virus , 2012, International journal of molecular sciences.

[3]  M. Arafa,et al.  Persistent Oxidative Stress in Patients with Chronic Active Hepatitis-C Infection After Antiviral Therapy Failure , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[4]  A. Craxì,et al.  Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[5]  H. Yen,et al.  Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C. , 2012, World journal of gastroenterology.

[6]  Zhiliang Gao,et al.  Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype , 2012, Virology Journal.

[7]  J. Dias,et al.  Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. , 2012, Gastroenterologia y hepatologia.

[8]  Mohammad Pessarakli,et al.  Reactive Oxygen Species, Oxidative Damage, and Antioxidative Defense Mechanism in Plants under Stressful Conditions , 2012 .

[9]  L. Vieira,et al.  Reactive Oxygen Species and Nitric Oxide in Cutaneous Leishmaniasis , 2012, Journal of parasitology research.

[10]  T. Wong,et al.  New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials , 2012, International journal of clinical practice.

[11]  K. Chayama,et al.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.

[12]  D. Pašalić,et al.  Uric acid as one of the important factors in multifactorial disorders – facts and controversies , 2012, Biochemia medica.

[13]  K. Diaz,et al.  Oxidative Stress Response to Short Duration Bout of Submaximal Aerobic Exercise in Healthy Young Adults , 2011, International journal of exercise science.

[14]  A. Craxì,et al.  Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.

[15]  D. Lavanchy,et al.  Evolving epidemiology of hepatitis C virus. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  W. Gomaa,et al.  Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[17]  M. El-Ghannam,et al.  Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[18]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[19]  D. Dieterich,et al.  Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin , 2009, Journal of viral hepatitis.

[20]  G. Esmat,et al.  Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C – genotype 4 , 2009 .

[21]  B. Halliwell The wanderings of a free radical. , 2009, Free radical biology & medicine.

[22]  S. Zeuzem,et al.  Occult hepatitis C: How convincing are the current data? , 2009, Hepatology.

[23]  B. Hunyady,et al.  [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study]. , 2009, Orvosi hetilap.

[24]  M. Rizzetto,et al.  Is serum uric acid a predictive factor of response to IFN‐treatment in patients with chronic hepatitis C infection? , 2008, Journal of medical virology.

[25]  S. Bruno,et al.  The natural course of HCV infection and the need for treatment. , 2008, Annals of hepatology.

[26]  J. Murray,et al.  Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations , 2007, Hepatology.

[27]  F. Izzo,et al.  Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis , 2007, Journal of gastroenterology and hepatology.

[28]  S. Kannan Multi-drug resistance : an intrinsic or acquired phenomenon , 2006 .

[29]  H. Esumi,et al.  Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. , 2005, The Journal of infection.

[30]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[31]  A. Folgori,et al.  Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance , 2004, Gut.

[32]  N. Waugh,et al.  Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.

[33]  D. Rockey,et al.  Nitric oxide biology and the liver: Report of an AASLD research workshop , 2004, Hepatology.

[34]  O. Aydın,et al.  Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis. , 2003, Hepato-gastroenterology.

[35]  M. Radomski,et al.  Distribution of nitric oxide synthase in normal and cirrhotic human liver , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. A. Callejas,et al.  Nitric Oxide in Liver Inflammation and Regeneration , 2002, Metabolic Brain Disease.

[37]  D. Sorbi,et al.  Nitric Oxide and Chronic HCV and HIV Infections , 2001, Digestive Diseases and Sciences.

[38]  G. Koraćević,et al.  Method for the measurement of antioxidant activity in human fluids , 2001, Journal of clinical pathology.

[39]  I. Young Measurement of total antioxidant capacity , 2001, Journal of clinical pathology.

[40]  B. Davidson,et al.  Hepatic and splanchnic nitric oxide activity in patients with cirrhosis , 1999, Gut.

[41]  N. Ballatori,et al.  Endogenous glutathione conjugates: occurrence and biological functions. , 1998, Pharmacological reviews.

[42]  B. Halliwell Free radicals, proteins and DNA: oxidative damage versus redox regulation. , 1996, Biochemical Society transactions.

[43]  J. Gutteridge,et al.  Lipid peroxidation and antioxidants as biomarkers of tissue damage. , 1995, Clinical chemistry.

[44]  P. Jansen,et al.  Nitrite and nitrate determinations in plasma: a critical evaluation. , 1995, Clinical chemistry.

[45]  M. Ruiz-Larrea,et al.  Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes , 1994, Steroids.

[46]  G. Cohen,et al.  Dopamine turnover and glutathione oxidation: implications for Parkinson disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Davies,et al.  Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. , 1986, The Biochemical journal.

[48]  B. Halliwell,et al.  Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.

[49]  B. Halliwell Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: a cause of chronic inflammatory disease? , 1982, Cell biology international reports.

[50]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. Berti,et al.  Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. , 1980, Clinical chemistry.

[52]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[53]  C. Piccoli,et al.  Targeting mitochondria in the infection strategy of the hepatitis C virus. , 2013, The international journal of biochemistry & cell biology.

[54]  R. Saller,et al.  The Use of Silymarin in the Treatment of Liver Diseases , 2012, Drugs.

[55]  R. Moreno-otero,et al.  Pathophysiological Basis for Antioxidant Therapy in Chronic Liver Disease , 2012, Drugs.

[56]  D. Harnois,et al.  Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .